TAFI polyclonal antibody

The Thrombin-activatable fibrinolysis inhibitor (TAFI), also designated procarboxypeptidase B2 or procarboxypeptidase U, is a hepatically secreted zymogen that downregulates fibrinolysis when activated by Thrombin. It is synthesized in the liver and circulates in plasma in its proenzyme form. When activated, TAFI removes C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins. TAFI cleaves the lysine residues from Fibrin, which prevents plasminogen from activation into plasmin and retards the lysis of a Fibrin clot. Elevated concentration of TAFI in blood is considered a risk factor for venous thrombosis, whereas a deficiency might contribute to the severity of bleeding disorders in hemophilias A and B. Decreased levels of TAFI are found in chronic liver disease.

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Western blot (WB) analysis of TAFI polyclonal antibody at 1:500 dilution LaneA:HepG2 whole cell lysate LaneB:The Liver tissue lysate of Mouse LaneC:The Liver tissue lysate of Rat